CR Double-Crane(SH:600062) Shang Hai Zheng Quan Bao·2025-12-23 20:17Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., received the clinical trial approval notice for the drug DC6001, which is intended for the treatment of Stargardt disease in adolescents [1][3]. Group 1: Drug Approval and Development - The drug DC6001 is aimed at treating Stargardt disease, a hereditary macular degeneration condition in adolescents [1]. - The clinical trial application for DC6001 was submitted to the National Medical Products Administration (NMPA) on October 9, 2025, and the approval notice was received on December 19, 2025 [1]. Group 2: Financial Investment - The total research and development investment for the drug DC6001 has reached approximately RMB 14.897 million (unaudited) as of the date of the announcement [2]. Group 3: Future Steps and Obligations - The company will actively promote the research and development project in accordance with national regulations and will fulfill its information disclosure obligations regarding subsequent progress [4].